IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

NLS Pharmaceutics LTD

CUSIP: H57830137 | 4 institutional holders

Quarters

Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q3 2025

BVF Inc143,676
0.0% of portfolio›$262.9K
UBS Group AG38
0.0% of portfolio›$70
StyleTurnoverLocationFiled
BVF Inc
143,676$262.9K0.0%CoreMediumSan Francisco, CA2025-11-14
UBS Group AG
38$700.0%CoreMediumZurich, Switzerland2025-11-13